NCT00198120.

Study name	Public title: Safety and effectiveness of D‐Cycloserine in children with autism Scientific title: A randomized controlled trial of D‐cycloserine in autism
Methods	Study design: randomised, double‐blind controlled trial Country: USA Study location: Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana
Participants	80 participants (age range = 3 to 12 years)
Interventions	Experimental intervention: D‐cycloserine Administration: 0.6 mg/kg/day in week 1; 1.1 mg/kg/day in week 2; 1.7 mg/kg/day in weeks 3‐8 Control intervention: placebo Administration: same dosing schedule and capsule strength
Outcomes	Primary outcome: core symptoms of ASD, social and communication impairment, measured by the Lethargy subscale of the Aberrant Behavior Checklist (ABC) Primary outcome: non‐core symptoms of ASD, measured by the Clinical Global Impression‐Improvement (CGI‐I) scale
Starting date	February 2004
Contact information	Principal investigator: Christopher J McDougle, MD Affiliation: Indiana University School of Medicine Telephone: 781‐860‐1783 Email: cmcdougle@partners.org
Notes	Sponsorship source: the study was funded by Indiana University. Comment: recruitment completed. No results posted on the trial register (clinicaltrials.gov/ct2/show/NCT00198120). The investigator did not respond to any of the three emails that we sent requesting further details on the trial.

ASD: autism spectrum disorder.